Across
- 3. Intravenous antiviral given for 14 days (for skin/eye/mouth disease) or 21 days (for CNS/disseminated disease) to treat neonatal Herpes Simplex Virus
- 7. Vitamin supplement co-administered at 5–10 mg/day with Isoniazid (INH) prophylaxis to prevent neurological side effects
- 9. Antimicrobial used alongside sulphadiazine and folinic acid for 12 months to treat a confirmed congenital toxoplasmosis infection
- 11. Specific type of penicillin (50,000 units/kg) given as a single intramuscular injection when congenital syphilis is deemed "less likely" or "unlikely"
- 12. Routine quantitative serological test evaluated in the infant's serum (not cord blood) to assess for congenital syphilis
Down
- 1. Preferred oral antiviral used for 6 months to treat moderate-to-severe symptomatic congenital Cytomegalovirus (CMV) infection
- 2. Antiretroviral drug paired with Nevirapine and given twice daily for high-risk HIV-exposed infants
- 4. Prophylaxis started at 4–6 weeks of age for all HIV-exposed infants and continued until HIV infection can be definitively excluded
- 5. Prophylaxis given daily for 6 weeks to an exclusively breastfed infant born to an HIV-positive mother with a suppressed viral load
- 6. Maternal treatment given before 18 weeks of gestation to reduce the transmission of Toxoplasma to the fetus
- 8. Prophylactic anti-tubercular drug given for 6 months (10 mg/kg/day) to an asymptomatic neonate born to a mother with Tuberculosis
- 10. Specific immunoglobulin administered intramuscularly within 12 hours of birth, alongside a vaccine, to infants born to Hepatitis B positive mothers